Onderzoeker
Niels Vande Casteele
- Disciplines:Laboratoriumgeneeskunde, Regeneratieve geneeskunde, Andere basiswetenschappen, Andere gezondheidswetenschappen, Andere medische en gezondheidswetenschappen, Medische biotechnologie, Farmaceutica, Ontdekking en evaluatie van geneesmiddelen
Affiliaties
- Therapeutische en Diagnostische Antilichamen (Afdeling)
Lid
Vanaf1 apr 2013 → 30 sep 2016
Projecten
1 - 1 of 1
- Vertaling van biofarmaceutische medicijnspiegels naar geïndividualiseerde zorg van patiënten met chronisch inflammatoir darmlijden door farmacometrische modellering en farmaco-economische evaluatie.Vanaf1 okt 2013 → 30 sep 2016Financiering: FWO mandaten
Publicaties
1 - 10 van 58
- Mucosal Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-based vs Trough Concentration-based Dosing of Infliximab(2018)
Auteurs: Marc Ferrante, Gert Van Assche, Paul Rutgeerts, João Guedelha Sabino, Niels Vande Casteele, Ann Gils, Séverine Vermeire
Pagina's: 1276 - 1283.e1 - Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial(2018)
Auteurs: Thomas Van Stappen, Niels Vande Casteele, Gert Van Assche, Marc Ferrante, Séverine Vermeire, Ann Gils
Pagina's: 818 - 826 - Evolving Concepts in Phases I and II Drug Development for Crohn's Disease(2017)
Auteurs: Niels Vande Casteele
Pagina's: 246 - 255 - Rapid Test for Infliximab Drug Concentration Allows Immediate Dose Adaptation(2016)
Auteurs: Thomas Van Stappen, Lize Bollen, Niels Vande Casteele, Gert Van Assche, Marc Ferrante, Séverine Vermeire, Ann Gils
- Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation(2016)
Auteurs: Niels Vande Casteele
Pagina's: 1685 - 1696 - Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab(2016)
Auteurs: Thomas Billiet, Niels Vande Casteele, Ann Gils, Marc Ferrante, Gert Van Assche, Paul Rutgeerts, Séverine Vermeire
Pagina's: 1015 - 1023 - Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results(2016)
Auteurs: Niels Vande Casteele
Pagina's: 1302 - 1309 - Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial(2016)
Auteurs: Niels Vande Casteele, Marc Ferrante, Ann Gils, Séverine Vermeire
Pagina's: 1126 - 1131 - Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis(2016)
Auteurs: Thomas Van Stappen, Niels Vande Casteele, Ann Gils, Thomas Billiet, Gert Van Assche, Paul Rutgeerts, Séverine Vermeire, Marc Ferrante
Pagina's: 543 - 549 - Analytical and clinical validation of a rapid point-of-care assay for infliximab quantification in patients with ulcerative colitis(2016)
Auteurs: Thomas Van Stappen, Lize Bollen, Niels Vande Casteele, Konstantinos Papamichael, Nick Geukens, Chris Barthel, Yessica Kölmel, Nasim Zali, Steffen Rameil, Gert Van Assche, et al.
Pagina's: S145 - S145